China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Sees Significant Growth in Short Interest

Posted by Stanley Muller on Aug 11th, 2026

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC – Get Free Report) was the recipient of a large increase in short interest during the month of July. As of July 31st, there was short interest totaling 4,613,535 shares, an increase of 20,385.5% from the July 15th total of 22,521 shares. Based on an average daily volume of 121,753,983 shares, the days-to-cover ratio is presently 0.0 days. Approximately 12.6% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded shares of China SXT Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a report on Tuesday, July 28th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Get Our Latest Report on SXTC

China SXT Pharmaceuticals Trading Down 2.2%

Shares of China SXT Pharmaceuticals stock traded down $0.08 on Tuesday, reaching $3.51. 246,186 shares of the company traded hands, compared to its average volume of 199,997. The company has a 50 day moving average of $135.26 and a 200 day moving average of $196.54. The company has a quick ratio of 7.76, a current ratio of 7.94 and a debt-to-equity ratio of 0.02. China SXT Pharmaceuticals has a 52 week low of $3.15 and a 52 week high of $83,758.80.

China SXT Pharmaceuticals (NASDAQ:SXTC – Get Free Report) last posted its quarterly earnings data on Wednesday, July 1st. The company reported ($5.60) EPS for the quarter. The company had revenue of $0.26 million during the quarter.

Institutional Investors Weigh In On China SXT Pharmaceuticals

Several large investors have recently added to or reduced their stakes in SXTC. Virtu Financial LLC raised its stake in China SXT Pharmaceuticals by 107.5% in the 3rd quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock valued at $46,000 after acquiring an additional 15,013 shares during the period. XTX Topco Ltd purchased a new position in shares of China SXT Pharmaceuticals in the fourth quarter worth about $36,000. Finally, Citadel Advisors LLC purchased a new position in shares of China SXT Pharmaceuticals in the third quarter worth about $78,000. Hedge funds and other institutional investors own 5.02% of the company’s stock.

About China SXT Pharmaceuticals

(Get Free Report)

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.